A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

This study tests a specialized eye implant called the Port Delivery System (PDS) with ranibizumab — a device surgically placed in the eye that continuously delivers a medication to treat neovascular age-related macular degeneration (nAMD). nAMD is a serious eye condition where abnormal blood vessels grow under the retina and leak fluid, damaging central vision. The implant is designed to provide long-lasting treatment without frequent eye injections. You may be eligible if... - You are 50 years of age or older - You have been diagnosed with nAMD within the past 9 months - You have had at least 3 anti-VEGF injections in the past 6 months and your eye has responded to treatment - Your best-corrected visual acuity is 20/200 or better - Your eye media is clear enough for retinal imaging You may NOT be eligible if... - You have had vitrectomy or other AMD-specific eye surgeries - You have previously received brolucizumab or gene therapy for the eye - You have active intraocular inflammation, vitreous hemorrhage, or glaucoma - You have more than 8 diopters of myopia - You have had intraocular surgery within 3 months of enrollment - You have a history of uveitis in either eye Talk to your doctor to see if this trial is right for you.